SAN FRANCISCO – A surviving son of a Ventura County man alleges a prescription drug his father took caused severe bleeding.
Craig Dutton, individually and on behalf of the estate of Charles Dutton, deceased filed a complaint on Feb. 5 in the San Francisco Superior Court against Boehringer Ingelheim Pharmaceuticals Inc., McKesson Corp. and Does 1 through 50 alleging negligence and other counts.
According to the complaint, Boehringer Ingelheim Pharmaceuticals sells and markets anticoagulant drug Pradaxa, which is distributed by McKesson. The suit states on June 5, 2017, Charles Dutton was prescribed Pradaxa for treatment of atrial fibrillation. Shortly after, he allegedly suffered anticoagulation-induced severe oral bleeding, causing him to be hospitalized at Community Memorial Hospital for a period of approximately three days. The suit states he died in November 2017.
The plaintiff holds Boehringer Ingelheim Pharmaceuticals Inc., McKesson Corp. and Does 1 through 50 responsible because Pradaxa is allegedly defective and unreasonably dangerous and its labeling failed to adequately warn users and physicians of the increased risk of excessive and/or uncontrollable bleeding.
The plaintiff requests a trial by jury and seeks judgment for general and special damages, loss of earnings, pre- and post-judgment interest, costs of suit and such other and further relief as the court may deem just and proper. He is represented by Mark A. Milstein and Levi M. Plesset of Milstein, Jackson, Fairchild & Wade LLP in Los Angeles.
San Francisco Superior Court case number CGC19573546